Latest TauRx Therapeutics Stories
Mediaplanet's digital campaign reveals that a recent breakthrough in Alzheimer's research may hold the key to the cure. New York, NY (PRWEB) June 13, 2013 A recently launched digital platform unveils a new breakthrough in Alzheimer’s research that is putting us on the brink of discovering a cure. This digital campaign, created by Mediaplanet, also explains the important role that clinical trials has and will continue to play in the quest for a cure. Click to access the full...
Dundee Corporation maintains 5% stake in company developing a revolutionary treatment for Alzheimer's Disease TORONTO and SINGAPORE, March 4, 2013 /PRNewswire/ -- TauRx Pharmaceuticals Ltd. ("TauRx") announced today the receipt of an equity investment of USD10.5m from Dundee Corporation of Toronto ("Dundee"). The investment will be used by TauRx primarily to support the on-going program of three Phase 3 clinical trials of LMTX(TM), its novel compound currently in development as a...
MANCHESTER, England, September 10, 2012 /PRNewswire/ -- Investigational drug study follows earlier study with promising results in mild to moderate Alzheimer's patients TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held...
A new finding suggests older adults with fewer fiber-like tangles of a protein linked with Alzheimer's stay sharper throughout life than those who age normally."This new finding in super aged brains is very exciting," said Changiz Geula, principal investigator of the study and a research professor of neurology at the Cognitive Neurology and Alzheimer's Disease Center at Northwestern's Feinberg School."Super-aged," means those people who maintain sharp cognitive skills in...
SAN FRANCISCO, Aug. 20 /PRNewswire/ -- Emerging therapeutic strategies for Alzheimer's disease is the focus of the most recent edition of Neurotech Insights, the leading monthly industry newsletter covering drugs, devices and diagnostics for the brain and nervous system. This month's feature article reviews the competing hypotheses around the cause of Alzheimer's disease including: the beta amyloid theory, tau hypothesis, the APOE4 and vascular theory, anti-inflammatories, memory enhancers,...
SCOTS scientists have developed a drug they say can halt the devastating progress of Alzheimer's disease. It could prove at least twice as effective in treating the disease as current medicines. The drug, known as rember, slows progression of the disease by as much as 81per cent. People taking it for 50 weeks had a slower decline in blood flow to the parts of the brain that are important for memory than those taking a dummy pill. Rember is the first drug to act on the 'tangles' that...
A NEW drug could prove at least twice as effective in treating Alzheimer's disease as current medicines, research has shown. The drug, rember, slows progression of the disease by as much as 81%, a British-led study found. People taking it for 50 weeks had a slower decline in blood flow to the parts of the brain that are important for memory than those taking a dummy pill. Rember acts on the tau tangles that develop in the brains of Alzheimer's sufferers. Made up of the protein tau,...
By Jeremy Manier, Chicago Tribune Jul. 31--Editor's note: Due to a production error, this story from Wednesday's newspaper did not run in full. This is the complete text. Hope is often scarce in research on Alzheimer's disease, but a study released Tuesday at a Chicago medical conference offered tentative hope for a new way of slowing elderly patients' mental decline. The preliminary study of 321 Alzheimer's patients from Singapore and Britain found that an old drug, previously used...
A NEW drug could prove at least twice as effective in treating Alzheimer's disease as current medicines, according to new research. The drug, rember, slows progression of the disease by asmuch as 81%, a British-led study published last night found. People taking it for 50 weeks had a slower decline in blood flow to the parts of the brain that are important for memory than those taking a dummy pill. Rember is the first drugto act on the tau tangles that develop in the brains of people...
An experimental Alzheimer's drug shows promise in halting progression of the disease through a new approach of dissolving the protein tangles that form in victims' brain.The results were announced Tuesday at a Chicago medical conference, and came as welcome news to an industry besieged with recent setbacks. The drug, called Rember, was developed by Singapore-based TauRx Therapeutics.But even if larger, more comprehensive tests prove Rember works, it would still be several years before the...
